A SU2C Catalyst Randomized Phase II Trial of the PD1 Inhibitor Pembrolizumab With or Without a Vitamin D Receptor Agonist Paricalcitol in Patients With Stage IV Pancreatic Cancer Who Have Been Placed in Best Possible Response
Latest Information Update: 29 Dec 2022
At a glance
- Drugs Paricalcitol (Primary) ; Pembrolizumab (Primary)
- Indications Adenocarcinoma; Pancreatic cancer
- Focus Therapeutic Use
- 06 Oct 2020 Status changed from active, no longer recruiting to completed.
- 12 Feb 2020 Status changed from recruiting to active, no longer recruiting.
- 17 Jul 2019 Planned End Date changed from 15 Dec 2019 to 15 Jun 2021.